# A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer

> **NCT07641855** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 180 (estimated)

## Conditions studied

- Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** BL-B01D1
- **DRUG:** Abiraterone
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT07641855
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07641855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07641855, "A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07641855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*